Highline Capital Management, L.P. Myovant Sciences Ltd. Transaction History

Highline Capital Management, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 17, 2021	SELL	$20.46 - $25.18 $1.37 Million - $1.69 Million	-67,100 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $925,980 - $1.85 Million	67,100 New	67,100 $1.85 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.